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Abstract LBP is one of the most common reasons for
visiting a doctor and is the most common cause of disability
under age 45.Amongst a variety of etiologies, internal disc
disruption (IDD) has been postulated as an important cause
of low back pain. Treating discogenic low back pain con-
tinues to be a challenge to physicians. Inﬂammation, either
from direct chemical irritation or secondary to an autoim-
mune response to the nucleus pulposus has been implicated
as the primary pain source. Both steroids and non-steroidal
anti-inﬂammatory drugs have partial effectiveness in
treating pain associated with inﬂammation. Therefore,
the rationale for using intradiscal steroids is to suppress
the inﬂammation within the disc, thereby alleviating the
patient’s symptoms. The goal of this article is to review the
literature regarding the efﬁcacy of intradiscal steroids to
treat low back pain of discogenic origin.
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Introduction
Low back pain (LBP) remains a major public health
concern in the US. LBP is one of the most common reasons
for visiting a doctor and is the most common cause of
disability under age 45 [1]. Approximately 60–80% of the
US population will experience back pain at some point in
their lives and 2–5% will have it at any given time [2].
According to recent estimates, the annual cost in the US is
between 100 and 200 billion dollars.
Amongst a variety of etiologies, internal disc disruption
(IDD) has been postulated as an important cause of low
back pain [3].
In 1970, Crock invented the term IDD as a condition
marked by alteration in the internal structure and metabolic
functions of the intervertebral disc, usually proceeded by
injuries [4]. He described IDD in a group of patients with
low back and leg pain who became worse after surgery for
a suspected disc prolapse [5]. Annular tears (including
radial and circumferential) are the major form of IDD. It is
generally accepted that the diagnosis of discogenic pain
due to IDD should meet the following criteria: (1) CT
discography reveals an IDD; (2) pain should be reproduced
on provocative injection of the contrast, and (3) as a con-
trol, stimulation of at least 1 other disc fails to reproduce
pain [6].
Discogenic back pain has been deﬁned clinically as
chronic low back pain of a deep aching, nagging, or
throbbing character, not completely relieved with rest, and
sometimes with referred pain to one or both limbs [7].
Treating discogenic low back pain continues to be a chal-
lenge to physicians. Over recent years, several minimally
invasive treatment modalities such as intradiscal steroid
injections, intradiscal electrothermal therapy (IDET), in-
tradiscal radiofrequency (RF) thermocoagulation, and
epidural steroid injections have been studied [8].
These methods have triggered a major interest among
interventional pain physicians and provide new alternatives
for patients with debilitating low back pain [9]. Although
the major advantages of minimally invasive therapies
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recovery time, and fewer long-term side effects when
compared with traditional surgery, many question their
efﬁcacy. The goal of this article is to discuss the rationale
for using intradiscal steroids and to review the literature
regarding the efﬁcacy of intradiscal steroids to treat low
back pain of discogenic origin.
Rationale for the use of intradiscal steroids
The intervertebral disc, which is composed of a central
nucleus pulposus and surrounding annulus ﬁbrosis, permits
mobility between opposing surfaces of the vertebral body.
It is ideally suited for the distribution and dissipation of
tremendous longitudinal forces.
The nucleus pulposus, can tolerate a static load indeﬁ-
nitely and adjust to ﬂuctuations through a physiologic
response in which there is a compensatory change in ﬂuid
retention. Since the nucleus acts as a conﬁned ﬂuid, it dis-
tributes vertical forces equally in all directions.
The annulus ﬁbrosus is a highly elastic tissue that sur-
rounds the nucleus pulposus and absorbs tangential forces.
With its low matrix content and high concentration of
ﬁbrous and elastic tissue, it thrives under tension but
deteriorates rapidly when subjected to direct pressure [9].
When degenerative changes exist in the nucleus pulpo-
sus, some of the force between the vertebral end plates is
exerted directly on the annulus ﬁbrosus. Degeneration of
some central ﬁbers appears ﬁrst, subsequently leading to
tears and ﬁssures. Although in the early phases these
changes are microscopic in appearance, they cause an
inﬂammatory reaction in the surrounding, sensitive, longi-
tudinal ligaments of the spine. This creates a clinical picture
of acute low back pain.
Inﬂammation, either from direct chemical irritation or
secondary to an autoimmune response to the nucleus pul-
posus has been implicated as the primary pain source [10].
Both steroids and non-steroidal anti-inﬂammatory drugs
have partial effectiveness in treating pain associated with
inﬂammation [11].
When the symptom of pain is thought to result from
inﬂammation, it is natural to think that an anti-inﬂammatory
agent can be useful for treatment. Therefore, the rationale for
using intradiscal steroids is to suppress the inﬂammation
within the disc, thereby alleviating the patient’s symptoms
[12].
Structurally, intradiscal steroids are thought to promote
spinal segment stabilization via further disc degeneration.
Yong-Hing and Kirkaldy-Willis described the ‘‘degenera-
tive cascade’’ of disc disease [13]. The cascade is divided
into three stages based on the amount of damage to the disc
and facet joints at a given point in time. This cascade of
individual motion segment degeneration is thought of as a
continuum rather than as three clearly deﬁnable and sepa-
rate stages.
The ﬁrst and second stages, dysfunctional and instability
stages, respectively, are ongoing ﬁssuring or tearing of the
outer annulus ﬁbrosus, decline in the amount of nuclear
proteoglycan composition, and patients presenting with
intense low back pain [14]. The third stage, stabilization, is
characterized by endstage tissue damage and attempts at
repair. Nucleus pulposus resorption occurs in this stage
resulting in worsening intervertebral disc space narrowing,
ﬁbrosis, endplate irregularities, and the formation of
osteophytes. The body restabilizes the segment and the
patient experiences fewer episodes of back pain [13].
Early studies have shown that after intradiscal injection,
radial bulges of the disc are decreased and its height is
increased, both are signs of spinal stabilization [15].
Additionally, Kato et al. [16] in 1993 concluded that disc-
ograms with intradiscal steroid injections bring about a
progressive degeneration of the intervertebral disc. Rather
than being a deleterious action, the degeneration of the disc
results in clinical improvement (i.e., pain reduction). This
occurs because the steroids cause a contraction of the tissue
and stabilization of the surrounding spinal segment.
Aoki et al. [17] followed these studies in 1997 and
evaluated histologic changes in intervertebral discs of
rabbits after intradiscal injection of corticosteroids. They
found that after 24 h, rabbits receiving methylprednisolone
acetate injection had degenerated tissue in the nucleus
pulposus and inner layer of the annulus ﬁbrosus. They also
observed matrix vehicles, an indication of primary tissue
calciﬁcation. They concluded that methylprednisolone
causes degeneration and primary calciﬁcation in discs. This
was proposed as the basis for the clinical improvement in
patients where steroids were used within the disc space for
the treatment of low back pain and sciatica.
Another practical reason for using intradiscal steroids is
that the administration of steroids can be performed at the
same time as a diagnostic discogram,without added mor-
bidity, time, or signiﬁcant expense.
Whether or not intradiscal steroids present a signiﬁcant
risk to patients remains an area of controversy. The risks of
spinal canal ossiﬁcation and calciﬁcation are low as con-
cluded by Ito et al. in patients who were followed for
5 years after undergoing discography and betamethasone
injection [18]. There have been, however, a few reported
cases of necrotic granulomatous lesions associated with
intradiscal steroids [19].
While the earlier trials of intradiscal steroids have
shown promising potential, more recent trials have been
less encouraging. We will review the earlier as well as
more recent studies on the use of intradiscal steroid for the
treatment of discogenic low back pain.
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In 1954, Feffer et al. [9] injected hydrocortisone into
the intervertebral discs of 244 patients and followed them
for 4–10 years. The population included both patients
with and without neurologic deﬁcits, who were deemed
good surgical candidates after receiving ‘‘extensive con-
servative care’’. In most of the cases, discograms were
performed by a posterolateral approach in which two
interspaces were injected with 25 mg of hydrocortisone.
The author attempted to correlate the level treated with the
clinical picture. Patients who responded favorably to the
injections were placed on a regimen of Williams-type
ﬂexion exercises. Most of those who did not respond
underwent a laminectomy.
The authors found that 114 of the 244 patients (46.7%)
obtained permanent remission from the hydrocortisone
injection. One hundred and thirty patients (53.3%) either
did not respond to the injection initially or relapsed.
In this study, although no single factor appeared to
designate a speciﬁcally favorable outcome, older patients
(greater than 30 years), patients whose pain was primarily
in the back rather than radicular, and those with limited
degenerative changes, had the best prognosis. Additionally,
the patients’ responses could not be predicted from the
character or duration of pain.
The only complication noted was one case of interspace
infection, which without surgery progressed to an asymp-
tomatic interbody fusion, suggesting faulty sterilization.
However, 2-year follow-up roentgenograms were obtained
and found ‘‘no unusual narrowing or acceleration of the
degenerative process.’’
Wilkinson et al. [20] performed 45 intradiscal injections
on 29 patients with lumbar disc disease. Ten of the patients
had back pain radiating to the legs and 19 had nonradiating
pain. All of the patients had symptoms for a minimum of
6 months, despite aggressive noninvasive therapy. None of
the patients were surgical candidates because they had no
objective neurological deﬁcits and many had atypical pat-
terns of pain. All patients underwent discography at the
time of intradiscal therapy and nearly all of them were
abnormal. The discogram abnormalities were generally
conﬁned to a single level and correlated closely with the
degenerative changes seen on plain ﬁlm. Early in the series,
eight injections were done using 30–40 mg of Depomedrol.
Subsequently, all intradiscal injections were done with 60–
80 mg of Depomedrol. All of the patients were followed
for a minimum of 1 year, with an average follow-up period
of 2.4 years. The authors found that in the group of patients
with discogenic pain, 54% responded poorly and only 31%
had good results lasting for more than 3 months.
In 1960, Leao et al. [21] studied 32 patients aged 18–70,
with low back and sciatic pain who failed conservative
therapy (rest, lumbosacral corset, and analgesics). Sixteen
of the patients received intradiscal hydrocortisone and the
remaining received intradiscal prednisolone. The dose of
steroid varied from 20–50 mg, but the ideal dose was
25 mg. The authors measured the patients’ response after
24 and 72 h in both groups as well as after 1 year in the
hydrocortisone group. They found that intradiscal steroids
produced beneﬁcial results in more than half the patients
and that there is no signiﬁcant difference between intradi-
scal hydrocortisone and prednisolone.
In 1975, Graham [22] reported a double blind study
comparing chemonucleolysis by chymopapain with intra-
discal hydrocortisone in a small group of 40 patients who
had chronic back pain and sciatica for several years and had
failed conservative therapy. Twenty patients were given
intradiscal chymopapain injections and 20 were given
intradiscal hydrocortisone. The patients were followed for
7 months and then either evaluated by a surgeon who was
blinded to the patients’ treatment or via questionnaire.
Twelve of the 20 patients (60%) receiving chymopapain
injectionshad‘‘fair togood’’resultsafter7 months,and10of
the19patients(53%)whoreceivedhydrocortisonehadsimilar
results. They found that chymopapain was not signiﬁcantly
superior to intradiscal injections of hydrocortisone.
This study attempted to prove the superiority of chy-
mopapain over steroids. The authors felt that was unethical
to inject placebo (saline) into the disc. Graham concluded
‘‘when one is considering the problem of a long-term back
sufferer, it is my ﬁrm belief that if half of the patients who
are subjected to intradiscal injection report back after
7 months and the result has been good, it is certainly a
worthwhile procedure [22].’’
Although the above studies show that intradiscal ste-
roids may be beneﬁcial when used in select patient
populations, they are merely case series and lack an ade-
quate control group. Also, due to their small sample sizes,
only limited conclusions may be drawn.
More recent studies
Due to the lack of objective scientiﬁc data in the above
studies, more recent trials were done in order to compare
intradiscal steroids to intradiscal placebo injections. In
1992, Simmons et al. [23] performed a randomized double
blind study to evaluate the efﬁcacy of intradiscal steroid
injections when compared with placebo (Bupivicaine). All
of the patients selected had only one level disc involvement
with or without sciatica and a positive pain response on
discography. They all had failed 6 weeks of conservative
treatment. Exclusion criteria were multilevel discs, central
or lateral stenosis, prior lumbar surgery, or medical disease
requiring steroids. A total of 25 patients were randomly
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Bupivicaine (Marcaine) (1.5 ml) and were re-evaluated
10–14 days after the injection. To measure the clinical
response,apaindiagramgridscore,avisualanalogscale,and
the Oswestry Pain questionnaire were used before injection
and after 10–14 days. Patients with objective signiﬁcant
improvement were entered into the appropriate rehabilitation
program, and conservative care was continued. Patients who
reported no improvement were considered clinical failures
and offered surgery when indicated.
Of the 25 patients studied, 14 received intradiscal
Depomedrol and 11 received intradiscal Bupivicaine. In the
Depomedrol group, 21% showed subjective improvement
and 79% showed no improvement. In the Marcaine group,
9% showed clinical improvement and 91% showed no
improvement. They concluded that there was no statisti-
cally signiﬁcant beneﬁt in using intradiscal steroids.
Khot et al. [7] performed a prospective randomized trial
comparing intradiscal steroids to placebo in patients with
lumbar discogenic pain. A total of 120 patients with chronic
discogenic low back pain who failed at least 6 weeks of
conservative care were randomized at the time of discog-
raphy to either an injection of normal saline or methylpred-
nisolone into the disc space. The patients were followed for
12 months and were asked to report their pain according to
a visual analog scale (VAS) and Oswestry Disability Index.
The primary outcome measure was the percentage change
in their disability. They found that there was no signiﬁcant
difference in the outcome between the two groups as the
steroid group had a mean change of 2.28% disability, while
the saline group had a mean percentage change of 3.42.
Also, with respect to pain scores, there was no signiﬁcant
difference.
The results of these two recent studies suggest that
intradiscal steroid injections do not improve clinical out-
comes in patients with discogenic back pain.
MRI changes after steroid injection
There have been several studies which suggest that a
patient’s clinical response to intradiscal steroids can be
predicted from their ﬁndings on MRI (i.e., Modic changes).
Modic changes on MRI were originally described by
Modic in 1988 [24]. MRI type 1 Modic changes are
decreased signal on T1, increased on T2, usually represent
marrow edema, and are associated with an acute process.
Type 2 changes, the most common type, are deﬁned as
increasedsignalonT1andisointenseorslightlyhyperintense
signal on T2. They represent fatty degeneration of subchon-
dral marrow and are associated with a chronic process. Type
3 changes represent decreased signal on both T1 and T2. It
correlates with bony sclerosis (no marrow) on radiographs.
Mayahi et al. [25] sought to determine whether clinical
outcome of patients with discogenic back pain who
underwent intradiscal steroid injections could be predicted
from MRI Modic changes.
Six months after an intradiscal steroid injection, clinical
outcomes were measured using visual analog scale and
Oswestry disability index. They observed that in patients
with Modic 1 vertebral end-plate changes, there was sig-
niﬁcant relief in 64% of patients and moderate relief in
29%. In those with Modic 2 changes, there was signiﬁcant
relief in 27% and moderate relief in 27%. In patients with
no Modic changes, there was improvement of low back
pain in only 9%. They concluded that patients with Modic
1 changes on MRI are most likely to beneﬁt from intradi-
scal steroid injections.
Bull et al. [26] studied the imaging of 125 patients who
had undergone discography and intradiscal steroid injec-
tions for low back pain. They were divided into Non-Modic
(61 patients), Type 1 Modic changes (20 patients), and
Type 2 Modic changes (24 patients). At 8 weeks post-
injection, the patients were assessed and classiﬁed as bet-
ter, the same, or worse. ‘‘Better’’ was deﬁned as complete
resolution of symptoms, or signiﬁcant reduction that
allowed return to normal activities.
In the Non-Modic group, 8 of 61 patients (13%) had
improved. In comparison, in the Type 1 Modic group, 4 of
the 20 patients (20%) improved and in the type 2 Modic
group, 13 of the 24 patients (54%) were better. From these
results, the authors concluded that many patients with Type
2 Modic changes on MRI, may have a chronic inﬂamma-
tory process which responds well to steroid injections.
More recently, Buttermann [27] studied the effect of epi-
dural and intradiscal steroid injections in patients with
degenerative disc disease (DDD), in an attempt to determine
whether patients with inﬂammatory end-plate changes on
MRI would respond more favorably to treatment.
Epidural steroid injections (ESI) were performed in 93
patients with degenerative disc disease and inﬂammatory
end-plate changes, and in 139 patients without inﬂamma-
tory end-plate changes. Additionally, patients with end-
plate changes (78) and those without changes (93), who
were considered candidates for lumbar fusion underwent
discography and were randomized as to whether they
received intradiscal steroids. Pain and function were pro-
spectively determined by a self-administered outcomes
questionnaire that consisted of a visual analog scale, pain
drawing, Oswestry Disability Index (ODI), and the patients’
opinion regarding treatment success. They were measured
before and after the patients’ injection for a 2-year follow-
up period.
The authors found that patients with inﬂammatory end-
plate changes had greater improvement in the ODI and pain
diagram in the ﬁrst 6 months than those without end-plate
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raphy led to signiﬁcant improvement in patients with
inﬂammatory end-plate changes in all outcome scales but
only minimal temporary improvement in patients without
end-plate changes. Buttermann concluded that spinal steroid
injections are more effective in patients with MRI ﬁndings of
inﬂammation, speciﬁcally adjacent end-plate changes.
Conclusion
Based on the current literature, it is unlikely that intradiscal
steroids offer much clinical improvement in pain or function
for patients with discogenic low back pain. While earlier
studies done without control groups have shown encouraging
results, more recent controlled trials reveal minimal if any
beneﬁt. Recent literature suggests that patients with Modic
changes on MRI and signs of end-plate inﬂammatory chan-
ges may beneﬁt the most from intradiscal steroid injections.
Research analyzing this subgroup may deﬁnitvely determine
whether there is a role in this subpopulation. Current litera-
ture does not support routine clinical use of intradiscal
steroids for the treatment of discogenic low back pain.
References
1. Woodwell D. National Ambulatory Medical Care Survey: 1996
Summary. Advance Data #295 1997.
2. Frymoyer JW. Lumbar disk disease: epidemiology. Instr Course
Lect 1992;41:217–23.
3. Bogduk N. The lumbar disc and low back pain. Neurosurg Clin N
Am 1991;2:791–806.
4. Crock HV. Internal disc disruption. A challenge to disc prolapse
50 years on. Spine 1986;11:650–3.
5. Crock HV. A reappraisal of intervertebral disc lesions. Med J
1970;1:983–9.
6. Merskey H, Bogduk N. Classiﬁcation of chronic pain: descrip-
tions of chronic pain syndromes and deﬁnitions of pain terms.
Seattle: IASP Press;1994. p. 180–1.
7. Khot A, Bowditch M, Powell J, Sharp D. The use of intradiscal
steroid therapy for lumbar discogenic pain: a randomized con-
trolled trial. Spine 2004;29:833–6.
8. Zhou Y, Abdi S. Diagnosis and minimally invasive treatment of
lumbar discogenic pain. A review of the literature. Clin J Pain
2006;22:468–81.
9. Feffer HL. Therpeutic intradiscal hydrocortisone: a long-term
study. Clin Orthop Relat Res 1969;67:100–4.
10. White AA, Gordon SL. Synopsis: workshop on idiopathic low-
back pain. Spine 1982;7:141–9.
11. Green LN. Dexamethasone in the management of symptoms due
to herniated lumbar disc. J Neurol Neurosurg Psychiatry 1975;38:
1211–7.
12. McCarron RF, Wimpee MW, Hudkins PG, et al. The inﬂamma-
tory effect of the nucleus pulposus. A possible element in the
pathogenesis of low back pain. Spine 1987;12:760–4.
13. Yong-Hing K, Kirkaldy-Willis WH. The pathophysiology of
degenerative disease of the lumbar spine. Orthop Clin North Am
1983;14:501–3.
14. Kirkaldy-Willis WH, Farfan HF. Instability of the lumbar spine.
Clin Orthop Relat Res 1982;165:110–23.
15. Brinckmann P, Horst M. The inﬂuence of vertebral body fracture,
intradiscal injection, and partial discectomy on the radial bulge
and height of human lumbar discs. Spine 1985;10(2):138–45.
16. Kato F, Mimatsu K, Kawakami N, et al. Changes in intervertebral
disc after discography with intradiscal injection of corticosteroids
observed with MRI. J Neurol Orthop Med Surg 1993;14:210–6.
17. Aoki M, Kato F, Mimatsu K, Iwata H. Histologic changes in the
intervertebral disc after intradiscal injections of methylpredniso-
lone acetate in rabbits. Spine 1997;22(2):127–31.
18. Ito S, Usui H, Maruyama K, Muro T. Roentgenographic evalu-
ation of ossiﬁcation and calciﬁcation of the lumbar spinal canal
after intradiscal betamethasone injection. J Spinal Disord 2001;
14(5):434–8.
19. Menei P, Fournier D, Alhayek G, Mercier P, Francois H, Audran
M, Guy G. Rev Rhum Mal Osteoartic 1991;58(9):605–9.
20. Wilkinson HA, Schuman N. Intradiscal corticosteroids in the
treatment of lumbar and cervical disc problems. Spine 1980;5:
385–9.
21. Leao L. Intradiscal injection of hydrocortisone and prednisolone
in the treatment of low back pain. Rheumatism 1960;16:72–7.
22. Graham CE. Chemonucleolysis: a preliminary report on a double
blind study comparing chemonucleolysis and intradiscal admin-
istration of hydrocortisone in the treatment of backache and
sciatica. Ortho Clin North Am 1975;6:259–63.
23. Simmons JW, McMillin JN, Emery SF, et al. Intradiscal steroids.
A prospective double blind clinical trial. Spine 1992;17:S172–75.
24. Modic MT, Steinberg PM, Ross JS, Masaryk TJ, Carter JR.
Degenerative disk disease: assessment of changes in vertebral
body marrow with MR imaging. Radiology 1988;166:193–9.
25. Mayahi R, Khot A, Sharp DJ, Powell J. Can modic changes on
MRI predict clinical response to steroids in discogenic low back
pain? J Bone Joint Surg (Br) 2005;87-B (Supp 3):233.
26. Bull TM, Sharp DJ, Powell JM. The efﬁcacy of intra-discal ste-
roid injection compared to modic changes in degenerate lumbar
discs. J Bone Joint Surg (Br) 1998;80-B(1S):47.
27. Buttermann GR. The effect of spinal steroid injections for
degenerative disc disease. The Spine J 2004;4:495–505.
Curr Rev Musculoskelet Med (2008) 1:103–107 107